Jeong J M, Kim Y J, Lee Y S, Ko J I, Son M, Lee D S, Chung J K, Park J H, Lee M C
Department of Nuclear Medicine, Seoul National University, 28 Yungun-dong Chongro-ku, Seoul 110-744, Korea.
Nucl Med Biol. 2001 Feb;28(2):197-204. doi: 10.1016/s0969-8051(00)00208-0.
Radiolabeled lipiodol has been used for targeting liver cancer. We developed a lipiodol solution of (188)Re-TDD (2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol) and investigated its feasibility for the treatment of liver cancer. The lipiodol solution of (188)Re-TDD was well-retained in the lipiodol phase in vitro. After injection through the tail veins of mice, high lung-uptake was investigated which is evidence of embolizing activity. We also found high accumulation in hepatoma after injection through the hepatic arteries of hepatoma-bearing rats. In conclusion, the lipiodol solution of (188)Re-TDD is a promising agent for liver cancer therapy.
放射性标记的碘油已被用于靶向肝癌。我们研发了一种（188）Re-TDD（2,2,9,9-四甲基-4,7-二氮杂-1,10-癸二硫醇）的碘油溶液，并研究了其治疗肝癌的可行性。（188）Re-TDD的碘油溶液在体外能很好地保留在碘油相中。通过小鼠尾静脉注射后，研究发现肺部摄取量高，这是栓塞活性的证据。我们还发现，通过荷肝癌大鼠的肝动脉注射后，肝癌中有高蓄积。总之，（188）Re-TDD的碘油溶液是一种有前景的肝癌治疗药物。
